This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2024
ASCO GU 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Upper Tract Urothelial Carcinoma
Press Releases
ASCO GU 2024 Bladder Cancer
Viewing 1-20 of 53 articles
ASCO GU 2024: Biology of Tumor Types: Radiation Versus Surgery
ASCO GU 2024: Phase 3 Open-Label, Randomized, Controlled Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)
ASCO GU 2024: Catalysts for Change: Patient Advocacy’s Role in Drug Shortages
ASCO GU 2024: Approach to the Platinum Shortage from a Community Oncologist Perspective
ASCO GU 2024: Phase 3 KEYNOTE-676 Cohort A: Bacillus Calmette-Guérin with or Without Pembrolizumab for High-Risk Non–muscle-Invasive Bladder Cancer That Persists/recurs After BCG Induction
ASCO GU 2024: Advanced Urothelial Carcinoma Discussant
ASCO GU 2024: Keynote Lecture - Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials
ASCO GU 2024: A New Era in the Perioperative Management of Muscle Invasive Bladder Cancer
ASCO GU 2024: Drug Sequencing, Pairing, Switching, and the Role of Checkpoint Re-Challenging
ASCO GU 2024: Drug Shortages: Why Are They a Recurrent Issue and What Can Regulatory Do to Prevent Them?
ASCO GU 2024: Lessons Learned: What Can Other Disease Sites Teach Us About Practical Implications of Checkpoint Therapy in Urothelial Carcinoma?
ASCO GU 2024: Surgical Therapeutic Role for Node-Positive Disease: Does It Make a Difference?
ASCO GU 2024: Harnessing the Power: Biologic Basis of Pairing and Sequencing Checkpoints with Other Therapy
ASCO GU 2024: Infigratinib vs Placebo in Patients with Resected Urothelial Cancer Bearing FGFR3 Mutation or Fusion: Primary DFS Analysis from the Phase 3, Randomized PROOF302 Study
ASCO GU 2024: Application of Artificial Intelligence Features of Nuclear Morphology from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Patients with MIBC Undergoing Cystectomy
ASCO GU 2024: RC48-ADC Versus BCG in Adjuvant Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer with HER2 Over-Expression: A Real-World Retrospective Study
ASCO GU 2024: Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD-1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations
ASCO GU 2024: Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NIMBC and Quantifies Molecular Response to Nadofaragene Firadenovec
ASCO GU 2024: Population Based Trends in Intravesical Gemcitabine Use Among Patients with High-Risk Non-Muscle Invasive Bladder Cancer
ASCO GU 2024: Reasons for Refusal of or Ineligibility for Radical Cystectomy in Patients with BCG–unresponsive High-Risk NMIBC from the SunRISe-1 Study
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free